Description
Release form
Coated tablets
Packing
10 pcs.
Pharmacological action
Clarithromycin-Teva – an antibiotic of the macrolide group – inhibits protein synthesis in a microbial cell by interacting with the 50S ribosomal subunit of bacteria. It is active against Streptococcus agalactiae (pyogenes, viridans, pneumoniae), Haemophilus influenzae (parainfluenzae), Neisseria gonorrhoeae, Listeria monocytogenes, Legionella pneumophilia, Mycoplasma pneumoniae, Helicobacterlomella chlamydermaera campelomella chlamdis pomori, Campilobrichrechljebrjebrjebrje dellum pertussis, Propionibacterium acnes, Mycobacterium avium, Mycobacterium leprae, Staphylococcus aureus, Ureaplasma urealyticum, Toxoplasma gondii. When ingested, clarithromycin is metabolized to form the main metabolite of 14hydroxyclarithromycin, which has the same or 1 2 orders of magnitude lower (depending on the type of microorganism) antimicrobial activity than unchanged substance.
Indications
Infections caused by microorganisms sensitive to clarithromycin – upper respiratory tract infections (laryngitis, pharyngitis, tonsillitis and sinusitis) lower respiratory tract infections (bronchitis, bacterial pneumonia) skin and soft tissue infections, folliculitis, folliculitis, folliculitis, infection) infections caused by Mycobacterium avium, Chlamydia trachomatis, Helicobacter pylori, Ureaplasma urealyticum.
Contraindications
hypersensitivity to the drugs of the
macrolide group, concomitant use of clarithromycin with the following drugs: astemizole, cisapride, pimozide and terfenadine
porphyria
pregnancy (I trimester) srdlk period lactation up to 12 years old.
Use during pregnancy and lactation
Use of Clarithromycin-Teva during pregnancy (II and III trimesters) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus. Clarithromycin is excreted in breast milk, so if you need to prescribe the drug during lactation, you should stop breastfeeding.
Special instructions
Use with caution in patients with impaired liver and / or kidney function. In the first trimester of pregnancy, prescribed only by absolute indications.
Composition
1 film-coated tablet contains:
Active ingredient – clarithromycin 500.0 mg
Excipients – povidone, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, 31 strontium white compound (sdlate 58: srdl5 containing hypromellose, lactose monohydrate, titanium dioxide (E171). macrogol 4000, sodium citrate).
Dosage and administration of
Clarithromycin-Teva is taken orally, adults and children over 12 years old – 250-500 mg 2 times a day. The duration of treatment is 6-14 days. In the treatment of infections caused by Mycobacterium avium, 500 mg is prescribed orally 2 times a day. The duration of treatment is 6 months or more. To eradicate Helicobacter pylori in patients with peptic ulcer and duodenal ulcer, clarithromycin is prescribed 250-500 mg twice a day as part of combination therapy. The duration of treatment is 7-14 days. In patients with chronic renal failure (creatinine clearance less than 30 ml / min or serum creatinine concentrations more than 3.3 mg / 100 ml) – 250 mg / day (once), in severe infections – 250 mg 2 times a day. The maximum duration of treatment in patients of this group is 14 days.
Side effects
Possible nausea, vomiting, epigastric pain, diarrhea, transient increase in hepatic transaminase activity, skin rash, headache.
Drug interaction
With the simultaneous administration of clarithromycin with theophylline and carbamazepine, an increase in the content of the latter in the blood plasma was noted.
Overdose
Symptoms: nausea, vomiting, diarrhea.
Treatment: wash your stomach as fast as possible, prescribe symptomatic therapy.
Storage Conditions
Store in a dry, dark place out of the reach of children at temperatures up to 25 ° C.
Active ingredient
Clarithromycin
Pharmacy terms
Prescription
Dosage form
tablet
Prescription
For children over 12 years old, Adults as prescribed by a doctor, Pregnant women as prescribed by a doctor, Children as prescribed by a doctor
Teva Pharmaceutical Enterprise Co., Ltd., Israel
